IVA

Inventiva S.A.
CAPPED RATING

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Inventiva S.A. (IVA) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (D-). The rating has held at D+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
D-
Factor Score 0.7 / 5.0
Growth
D-
Factor Score 1.1 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.6
EV / EBITDA -6.2
Rev Growth YoY -76.7%
Gross Margin 78.3%
Price Return 3M -12.8%
Price Return 12M 6.9%
Catalyst Signal 0.00
Market Cap $958.8M
TTM Revenue $2.5M
Price / Sales 390.4
ROE N/M

Historical Factor Score Progression

Held D+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 D- (0.7) D- (1.1) C- (2.1) C- (1.9) C+ (2.6) D+ (1.7)
2026-11-05 D- (0.9) D- (0.7) C- (2.1) C- (2.0) C+ (2.7) D+ (1.7)
2026-10-29 D- (1.0) D- (0.7) C- (2.0) D+ (1.7) C+ (2.7) D+ (1.6)
2026-10-22 D- (1.0) D- (0.7) C- (2.0) D+ (1.7) C+ (2.6) D+ (1.6)
2026-10-15 D (1.3) F (0.7) C- (2.0) D+ (1.6) C+ (2.6) D+ (1.6)
Page 1 of 4